This post may refer to COVID-19
To access official information about the coronavirus, access CDC - Centers for Disease Control and Prevention.
Tobacco-Based COVID-19 Vaccine Got FDA Approval for Human Trials
British American Tobacco has won the FDA's approval to start human clinical trials of its tobacco-based COVID-19 vaccine. Read the details here.
Using tobacco plants to create a vaccine against COVID-19 has moved one step closer to becoming a reality.
The U.S. Food and Drug Administration (FDA) has officially approved British American Tobacco (BAT) to start human clinical trials of its COVID-19 vaccine.
If the trials go well, it'll join the ranks of other vaccines currently already in production. However, BAT's one can be produced in just six weeks, compared to months with conventional methods. It can also be kept at room temperature, versus freezing conditions for some other vaccines.
The reason BAT's vaccine can be produced so quickly is that elements of it are rapidly gathered on tobacco plants, the company's staple good.
Developed by its biotechnology division, called Kentucky BioProcessing (KBP), the company cloned a section of the genetic sequence of the coronavirus and developed a potential antigen. The latter is then inserted into tobacco plants for reproduction.